Study Population Inclusion Criteria Aged 18 to 80 years, regardless of gender; Stable vital signs, eligible for routine cerebral digital subtraction angiography (DSA); Suspected intracranial vascular lesions (stenosis, aneurysm, malformation, etc.) by computed tomography angiography (CTA)/magnetic resonance angiography (MRA) requiring further confirmation, or need to clarify the blood supply of intracranial space-occupying lesions/qualification of tumors; Positive Allen's test; Ultrasound shows radial artery diameter >2.0 mm, or <2.0 mm but still eligible for transradial angiography as evaluated by senior physicians.

Exclusion Criteria Patients with contrast medium allergy; Patients with acute hemorrhagic/ischemic cerebrovascular disease requiring emergency cerebral DSA, and patients with unstable acute stroke; Patients with severe vascular malformation/stenosis/occlusion, severe hepatic and renal insufficiency, severe hypertension/hypotension, severe infection, coagulation dysfunction, severe cardio-cerebro-pulmonary diseases, congestive heart failure; Pregnant/lactating women and women planning to become pregnant within 1 year; Patients clinically ineligible for cerebral DSA; Patients with fear of interventional robots and refusal of robot-assisted angiography.

Sample Size: A total of 156 cases, 78 cases in the experimental group (robot-assisted group) and 78 cases in the control group (manual group) (74 cases per group in basic calculation, expanded considering a 5% loss rate).

Randomization and Blinding Randomization: Block randomization mode, led by an independent third party (Randomization Management Group, non-surgical/evaluation staff); clinical medical staff are only responsible for screening, informed consent and surgery implementation. After assigning a unique number to enrolled patients, the clinical research coordinator (CRC) completes random grouping, and grouping information is confidentially filed.

Blinding: Blinded outcome assessors (CRF recorders not involved in surgery), blinded data analysts (groups coded as Group A/B during statistical analysis, decrypted after analysis); an emergency unblinding mechanism is established, unblinding is allowed in case of serious adverse events, and data are marked separately after unblinding.

Study Endpoints Primary Endpoints Technical success rate of intracranial major vascular angiography: Accurate positioning of target vessels for angiography with qualified image quality; Clinical success rate of intracranial major vascular angiography: Completion of angiography for at least 4 supra-aortic major arteries (bilateral common carotid arteries + bilateral subclavian arteries).

Secondary Endpoints Incidence of various perioperative and postoperative complications; Total radiation dose received by patients and primary surgeons; Total duration of the entire angiography process, robot installation time, and single angiography duration of each intracranial vessel; Targeting accuracy of the operation; Patient satisfaction and comfort; Surgeon learning curve; Cost-effectiveness analysis.

Study Risks and Benefits Benefits Expand the application scope of robots and improve patients' surgical comfort; Clarify the accuracy and reliability of robot-assisted transradial angiography, achieving a success rate comparable to manual angiography; Reduce occupational radiation damage to physicians and realize robot-assisted remote compartment "zero-radiation" operation.

Risks Routine risks of cerebral DSA: Cardiac events, cerebrovascular events, adverse reactions to contrast medium, vascular rupture/thrombosis/spasm/dissection, puncture site hematoma/pseudoaneurysm, etc.; Very low probability of device-related risk: Vascular injury caused by unintended movement of the robot.